Rahul Gosain, MD, of the Oncology Brothers, talks with Mafalda Oliveira, MD, PhD, about the emerging class of drugs — including oral SERDs and PROTAC estrogen receptor degraders — and whether they are working better for patients.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Next Generation Endocrine Therapy
Join the global breast cancer community for four days of research spanning experimental biology, etiology, translational science, prevention, diagnosis and treatment, December 8-11 in San Antonio, Texas.
Share: